Core Insights - Michael Dion is an expert in FP&A, Corporate Finance, and Small Business with 12 years of experience in Fortune 100 companies and various industries [1] - He founded F9 Finance to assist finance professionals and small business owners in understanding finance and accounting concepts [1] - Dion's investment strategy focuses on identifying value opportunities where market reactions to news are disproportionate, emphasizing strong fundamentals and dividends [1] Industry Insights - The finance and accounting sectors are increasingly recognizing the importance of cash flow for both companies and investors [1] - There is a growing trend of small businesses seeking guidance from experienced finance professionals to enhance their financial management [1]

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

NovoCure (NVCR) reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a year ago.The reported revenue represents a surprise of -0.02% over the Zacks Consensus Estimate of $161.3 million. With the consensus EPS estimate being -$0.34, the EPS surprise was -79.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -79.41%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.34 per share when it actually produced a loss of $0.28, delivering a surprise of 17.65%.Over the last four quarters, the company ha ...

Company Overview - NovoCure Limited held its Q4 2024 Earnings Conference Call on February 27, 2025, at 8:00 AM ET, featuring key executives including Chairman Bill Doyle, CEO Ashley Cordova, and CFO Christoph Brackmann [1][3]. Conference Call Structure - The conference call began with an introduction by Ingrid Goldberg, who welcomed participants and outlined the agenda, which included a presentation followed by a question-and-answer session [2][3]. Financial Performance - The call aimed to review NovoCure's fourth quarter and full year 2024 performance, with accompanying slides available on the company's Investor Relations page [3].

NovoCure Limited (NASDAQ:NVCR) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Executive Officer Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive Vice President & President, NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Lei Huang - Wells Fargo Vijay Kumar - Evercore IS ...

Confidential © 2024 Novocu © 2025 re GmbH Novocure GmbH 1 © 2025 Novocure GmbH 2 GROW GBM LAUNCH LUNG DELIVER PIPELINE • •• © 2025 Novocu r e GmbH GmbH 3 ••• •• • © 2025 Novocure GmbH GmbH 4 | ✓ | | | | --- | --- | --- | | ✓ | ✓ | | | ✓ | ✓ | | | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | | ✓ | • | • | | • | | | © 2025 Novocu r e GmbH 5 © 2025 Novocure GmbH 6 | U.S. DOLLARS IN MILLIONS | | Q4 2024 | | Q4 2023 | | FY 2024 | | FY 2023 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Net revenues | ഗ | ...

EXHIBIT 99.1 Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43 Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 rd BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ For the fiscal year ended December 31, 2024 or (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu ...

Core Viewpoint - The market anticipates NovoCure (NVCR) to report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2024, with actual results being crucial for stock price movement [1][2]. Financial Expectations - NovoCure is expected to report a quarterly loss of $0.34 per share, reflecting a year-over-year change of +24.4% [3]. - Revenue projections stand at $161.3 million, indicating a 20.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.03% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for NovoCure is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -27.91% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced positive surprises nearly 70% of the time [8]. Historical Performance - NovoCure has beaten consensus EPS estimates in the last four quarters, with a notable surprise of +17.65% in the last reported quarter [12][13]. Industry Comparison - Fate Therapeutics (FATE), another player in the biomedical sector, is expected to report an EPS of $0.44 for the same quarter, with a year-over-year change of +2.2% and revenues expected to decline by 24.4% [17]. - Fate Therapeutics has seen a 0.2% increase in its consensus EPS estimate over the last 30 days, but its Earnings ESP stands at 3.82% combined with a Zacks Rank of 4, making predictions of an earnings beat challenging [18].